Cargando…
Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
The development of a single immuno-metabolic adjuvant capable of modulating, in the appropriate direction and intensity, the complex antagonistic and symbiotic interplays between tumor cells, immune cells, and the gut microbiota may appear pharmacologically implausible. Metformin might help solve th...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791450/ https://www.ncbi.nlm.nih.gov/pubmed/31646077 http://dx.doi.org/10.1080/2162402X.2019.1633235 |
_version_ | 1783458980979277824 |
---|---|
author | Verdura, Sara Cuyàs, Elisabet Martin-Castillo, Begoña Menendez, Javier A. |
author_facet | Verdura, Sara Cuyàs, Elisabet Martin-Castillo, Begoña Menendez, Javier A. |
author_sort | Verdura, Sara |
collection | PubMed |
description | The development of a single immuno-metabolic adjuvant capable of modulating, in the appropriate direction and intensity, the complex antagonistic and symbiotic interplays between tumor cells, immune cells, and the gut microbiota may appear pharmacologically implausible. Metformin might help solve this conundrum and beneficially impact the state of cancer-immune system interactions. |
format | Online Article Text |
id | pubmed-6791450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-67914502019-10-23 Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy Verdura, Sara Cuyàs, Elisabet Martin-Castillo, Begoña Menendez, Javier A. Oncoimmunology Point-of-View The development of a single immuno-metabolic adjuvant capable of modulating, in the appropriate direction and intensity, the complex antagonistic and symbiotic interplays between tumor cells, immune cells, and the gut microbiota may appear pharmacologically implausible. Metformin might help solve this conundrum and beneficially impact the state of cancer-immune system interactions. Taylor & Francis 2019-06-25 /pmc/articles/PMC6791450/ /pubmed/31646077 http://dx.doi.org/10.1080/2162402X.2019.1633235 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Point-of-View Verdura, Sara Cuyàs, Elisabet Martin-Castillo, Begoña Menendez, Javier A. Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy |
title | Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy |
title_full | Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy |
title_fullStr | Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy |
title_full_unstemmed | Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy |
title_short | Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy |
title_sort | metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy |
topic | Point-of-View |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791450/ https://www.ncbi.nlm.nih.gov/pubmed/31646077 http://dx.doi.org/10.1080/2162402X.2019.1633235 |
work_keys_str_mv | AT verdurasara metforminasanarchetypeimmunometabolicadjuvantforcancerimmunotherapy AT cuyaselisabet metforminasanarchetypeimmunometabolicadjuvantforcancerimmunotherapy AT martincastillobegona metforminasanarchetypeimmunometabolicadjuvantforcancerimmunotherapy AT menendezjaviera metforminasanarchetypeimmunometabolicadjuvantforcancerimmunotherapy |